Oxatomide is a new anti-allergy drug, derived from benzamidazole, which has shown original pharmacological properties at different stages of the degranulation of mastocytes and basophils, inhibition of the increase of intracellular calcium, inhibition of histamine release and of the synthesis of leukotrienes and prostaglandins. In addition, it has an antagonistic action on the histamine H1 receptors and inhibits the effects of serotonin and SRSA leukotrienes. Clinical trials have shown the clinical efficacy of oxatomide on chronic urticaria and atopic dermatitis, double blind against placebo. Also its action is quicker than certain reference molecules with which it was compared. The product seems to have excellent tolerance. Oxatomide is a molecule of which the pharmacological properties are coupled with clinical efficacy on allergic dermatoses.